Tegafur,Gimeracil and Oteracil Potassium

Locations: 🇯🇵
National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Aichi Cancer Center, Nagoya, Aichi, Japan

and more 19 locations

A Trial of TAS-114 in Combination With S-1

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS-114
Drug: S-1

First Posted Date: 2015-05-27

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 120

Registration Number: NCT02454062

Locations: 🇧🇪
Erasme University Hospital-ULB, Brussels, Belgium
🇮🇹
IRCCS San Marino IST, Genoa, Italy
🇨🇭
IOSI Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

and more 2 locations

A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan

Phase 1

Completed

Conditions: Digestive Cancer

Interventions: Drug: S-1
Drug: Irinotecan
Drug: Oxaliplatin
Other: G-csf

First Posted Date: 2015-03-12

Last Posted Date: 2019-08-22

Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Target Recruit Count: 24

Registration Number: NCT02387138

Locations: 🇫🇷
Institut du Cancer de Montpellier - Val d'Aurelle, Montpellier, France

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: cisplatin
Drug: nimotuzumab
Drug: S-1

First Posted Date: 2015-02-25

Last Posted Date: 2015-02-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2

Registration Number: NCT02370849

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Ramucirumab
Drug: Capecitabine
Drug: Cisplatin
Drug: S-1
Drug: Oxaliplatin

First Posted Date: 2015-02-09

Last Posted Date: 2018-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT02359058

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Ehime, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Osaka, Japan

Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

Phase 3

Active, not recruiting

Conditions: Stomach Neoplasms
Gastric Cancer

Interventions: Drug: oxaliplatin
Drug: etoposide
Drug: pharmorubicin
Drug: S-1

First Posted Date: 2015-01-14

Last Posted Date: 2023-09-29

Lead Sponsor: Jinling Hospital, China

Target Recruit Count: 297

Registration Number: NCT02338518

Locations: 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China

Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

Phase 3

Conditions: Esophageal Neoplasms

Interventions: Drug: S-1
Drug: S1
Drug: irinotecan

First Posted Date: 2014-12-18

Last Posted Date: 2015-08-03

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 240

Registration Number: NCT02319187

Locations: 🇨🇳
Hunan Cancer Hospital,the Affiliated Cancer Hospital of Xianya School of Medicine, Changsha, China
🇨🇳
Herbin Medical University Cancer Hospital, Herbin, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, China

and more 10 locations

A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Chemoradiotherapy
Chemotherapy
Neoadjuvant Therapy
Stomach Neoplasms

Interventions: Procedure: Surgery
Radiation: SIB-IMRT
Drug: S-1
Drug: SOX

First Posted Date: 2014-11-26

Last Posted Date: 2019-10-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 71

Registration Number: NCT02301481

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

A Phase II Study of Postoperative S-1-Based Chemoradiotherapy in Gastric Cancer

Phase 2

Conditions: Stomach Neoplasms
Radiotherapy, Intensity-Modulated
Chemoradiotherapy, Adjuvant

Interventions: Radiation: intensity-modulated radiotherapy
Drug: S-1

First Posted Date: 2014-11-20

Last Posted Date: 2014-11-20

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT02296658

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy